Continuous terbutaline nebulization for the treatment of severe exacerbations of asthma in children

Area of Science:

• Pediatric critical care
• Respiratory medicine
• Pharmacology

Background:

• Severe asthma exacerbations in children pose significant management challenges.
• Continuous nebulization of beta-agonists is a potential therapeutic strategy for severe asthma.

Purpose of the Study:

• To evaluate the safety and efficacy of continuous nebulized terbutaline in pediatric patients with severe asthma.
• To assess clinical outcomes and side effects associated with this treatment modality.

Main Methods:

• Twelve pediatric patients with severe asthma were treated in an intensive care unit.
• Continuous nebulized terbutaline was administered at doses ranging from 1.0 to 12.0 mg/hour.
• Treatment duration varied from 1 to 24 hours.

Main Results:

• All patients demonstrated improvements in blood gases, pulse rate, and respiratory rate.
• No significant adverse events were observed during the treatment period.
• The mean duration of therapy was 8.3 hours.

Conclusions:

• Continuous nebulized terbutaline is a safe and effective treatment for severe pediatric asthma.
• Patients treated with this method were discharged from the intensive care unit within 24 hours.
• Further investigation in larger cohorts is warranted to confirm these findings.